Heyuan Bio's China-Originated CAR-T Therapy Yuoruida® (Najiorunse Injection) Granted Conditional Approval for Leukemia Treatment

On November 8, the National Medical Products Administration (NMPA) granted conditional approval for the marketing of Juventas' immunocellular CAR-T therapy product, Yuan Ruida® (Natiecolisib Injection, Inaticabtagene Autoleucel Injection, CNCT19 Cell Injection). This provides a new treatment option for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Najio Longcell Injection is the first CD19 CAR-T cell therapy product with full independent intellectual property rights in China, and also the first CAR-T cell therapy product in the field of leukemia treatment in China. The Weipu Pharmaceutical Packaging and Production System Research Service Platform provided professional technical services for this product, including packaging material compatibility, production system compatibility, drug delivery device compatibility, and container closure integrity.

Chinese Original! Juventas' Leukemia Treatment CAR-T Product Yuanruida® Conditionally Approved for Market Launch

Leukemia is one of the most common hematological malignancies, especially in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), where there is a significant unmet clinical need. Innovative therapeutic products are urgently required to extend patient survival and improve their quality of life.

Najiolunsa Injection is an autologous T-cell immunotherapy product prepared using gene modification technology to express chimeric antigen receptors (CAR) targeting CD19 on the surface of T cells. After infusion into the body, it binds to target cells expressing CD19, activates downstream signaling pathways, induces CAR-T cell activation and proliferation, and exerts cytotoxic effects on target cells. This is a China-developed CD19 CAR-T cell therapy product with full independent intellectual property rights, and also the first CAR-T cell therapy product in the field of leukemia treatment in China. With its unique CD19scFv (HI19a) structure and advanced manufacturing process, it has demonstrated sustained high remission rates and significantly reduced severity of CAR-T treatment-related toxicity in pivotal clinical studies for treating adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

Spare No Effort to Meet Expectations: Pharmaceutical Packaging Materials and Production System Research and Service Platform

Compared with traditional small molecule drugs, biologics pose greater challenges to the entire R&D process due to their structural and process complexity. In the research of Juventas' Nalkiolec Injection, Microspectrum's pharmaceutical packaging material and production system research service platform provided professional technical services such as packaging material compatibility, production system compatibility, drug delivery device compatibility, and container closure integrity, assisting in the approval and market launch of China's self-developed CAR-T product for leukemia treatment!

The service capabilities of Microspectrum's pharmaceutical packaging materials and production system research service platform cover professional services such as compatibility, seal integrity, pharmaceutical packaging material testing, filter validation, and safety evaluation. With an experienced team of experts and systematic integrated R&D capabilities, the platform provides customers with professional one-stop solutions, continuously helping pharmaceutical partners reduce R&D risks, shorten R&D cycles, save R&D costs, and accelerate product market entry!

Spare no effort and live up to the trust. In the future, the Weipu Pharmaceutical Packaging Materials and Production System Research Service Platform will continue to rely on a systematic research process and technical approach developed in the biologics research field. Empowering more customers to bring innovative products to market quickly, and living up to the trust and support of industry partners!

Editor: Baiji

Disclaimer: This article is a reprint from PharmaSmart, with all images and text copyrighted by the original author. The purpose of the reprint is to convey more information and does not represent the views of this platform. If there are any issues regarding the content, copyright, or other aspects, please leave a message on this platform, and we will address it promptly.